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Abstract
The second incidence of brain metastases is from breast cancer. Radiotherapy, a standard
treatment for brain metastasis, limits cancer division by inducing DNA double-stranded
breaks (DSBs). Currently, identical radiation doses are prescribed for all types of brain
metastases but little is known about their histological responses. In this thesis, we initiated a
radiation dose-response study in a triple-negative human breast cancer brain metastasis
mouse model using a custom designed 3D-printed restrainer to assist half-brain irradiation.
We quantified the amount of DSBs in tumors and mouse brain tissues using γ-H2AX marker
at 30 minutes (acute) and 11 days (longitudinal) after treatment with doses of 8-24 Gy. We
also evaluated tumors’ response using histology and MRI. In the longitudinal study we found
significant differences in the amount of DSBs, tumor cell density, and nucleus size between
irradiated surviving and non-irradiated tumors. These results gave insights to brain metastasis
response after radiotherapy.

Keywords
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Chapter 1

1

General Introduction
Cancer is one of the most severe and potentially life-threating diseases. The high

morbidity and mortality rate is primarily due to the progression to the metastatic stage.
Radiation therapy has been, and continues to be, an important treatment modality for
patients diagnosed with cancer.

This is especially true in the treatment of brain

metastases because of limited drug penetration through the blood brain barrier, or tumors
become refractory after multiple lines of chemotherapies, or appear in locations that are
inoperable, leaving radiation therapy the only management option. Mechanisms of tumor
response/resistance to radiation therapy remain unclear. With the advent of new
biological markers, tumor models and novel imaging techniques, we revisit these
radiobiological challenges in the preclinical setting. This introductory chapter provides an
overview of breast cancer and brain metastasis from this origin, treatment options,
principles of radiobiology as well as techniques for quantifying radiation damage,
preclinical radiation therapy and imaging technique used in this thesis.

1.1 Cancer
1.1.1

Breast Cancer
Breast cancer is the most common malignancy among both American and

Canadian women.[1,2] It is estimated in 2015, 231,840 women in the USA and 25,000 in
Canada will be diagnosed with breast cancer.[2,3] Breast cancer also has the second
highest mortality rate after lung and bronchus cancer in women. This cancer has a low
incidence in men and accounts for less than 1% of all breast cancer cases.[2,3]
Breast cancer is a heterogeneous disease. There is diversity in breast cancer morphology
and characteristics, response to treatment and patient’s clinical outcome. The high degree
of heterogeneity can be seen in breast cancer structure, pathological features and even

1

within an individual tumor.[4] Breast cancer can be segregated into three groups based on
its structure and origin:
1) Invasive ductal carcinoma, 75% of cases,
2) Invasive lobular carcinoma, ~15% of cases, and
3) Other types such as medullary, neuroendocrine, tubular, apocrine, metaplastic, adenoid
cystic and micropapillary, ~10% of cases.[4,5]
Another approach to classify breast cancer is by their histopathological
characteristics. Based on the status of hormone receptors such as estrogen (ER) and
progesterone (PR), overexpression of the human epidermal growth factor receptor 2
(HER2) oncogene and Ki-67 labeling index, a proliferation marker, breast cancer has
been classified to four major subtypes.[6,7] Although there are other classifiers for breast
cancer, histopathological markers are known to be widely adopted in the clinics.[4,8,9]
Table 1-1 shows breast cancer subtypes based on their molecular markers and their
prevalence. Other subtypes of breast cancer such as normal like, apocrine molecular type
and claudin-low type, are less frequent.
The status of the receptors is a critical predictor of both treatment decision and
patient prognosis. Subtypes that express receptors on their surface are known to be
suitable candidates for hormonal and targeted therapy. For example, Trastuzumab
(Herceptin) is a monoclonal antibody that is currently used as an adjuvant treatment in
early stage HER2 positive patients.[10] On the other hand, subtypes such as triple-negative
do not have a well-defined therapy targets.[4]
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Table 1-1: Breast cancer classification based on histopathological markers [6,8]

Breast cancer subtype

Approximate
prevalence

Marker expression status

Luminal-A

50-60%

HER2 negative, ER and/or PR
positive, Ki-67 low

Luminal-B

15%-20%

HER2 negative, ER positive,
either Ki-67 high or PR low
HER2 positive, ER positive,
any Ki-67, any PR

HER2 overexpression

15-20%

HER2 positive and amplified,
ER and PR negative

Triple - negative

15-25%

HER2 negative, ER and PR
negative

1.1.2

Triple-Negative Breast Cancer Subtype
The triple-negative breast cancer (TNBC) subtype is defined by the absence of

hormone receptors (ER, PR) and lack of HER2 expression on immunohistochemical
(IHC) analysis in the clinical setting.[6] In this thesis, we employed a TNBC cell line for
our radiation dose-response study. Most of the TNBC cells have a ductal origin (90.7%)
and are poorly differentiated.[11] This breast cancer subtype occurs more in young
women, with African or Hispanic ancestry.[12] Triple-negative breast cancer usually
associated with poor prognosis and aggressive clinicopathological features.[13] Less than
30% of triple-negative patients survive more than 5 years.[12] TNBC has also a distinct
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recurrence pattern. Patients diagnosed with triple-negative breast cancer are frequently
young and recurrence occurs 3 to 5 years after initial diagnosis. The incidence of late
recurrence (more than 5 years) in these patients is lower compared to other breast cancer
subtypes.[11] The treatment of triple-negative cells remains challenging. The primary
reason is, this subtype does not express ER/PR and HER2 receptors on the cell surface
which limits the use of endocrinal therapy or available targeted drugs.[12] Breastconserving surgery followed by radiation therapy and/or cytotoxic chemotherapy are the
common treatment options for these patients.

1.1.3

Metastasis
Frequently, it is not the primary cancer that a patient succumbs to, but what makes

cancer a life-threating disease is when it gains the ability to escape from the primary site
and spread to other organs. This process is known as metastasis.[14] Most of the tumors
select either lymphatic or hematogenous (blood-stream) routes to leave the primary
organ.[15] However, when these cells are in the circulatory system, the pattern and the
micro-environmental conditions in the host organs play a crucial role in the ultimate fate
of the primary tumor cells.[16–18] Metastasis is an inefficient process, and usually less than
0.01% circulating tumor cells can complete all the steps shown in Figure 1-1 and form
metastasis

[15,17,19]

; thus this tiny subset is responsible for the majority of cancer deaths.

As we will be using a preclinical brain metastasis model in this thesis, we will focus on
brain metastasis next.
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Intravasation

Brain metastatic lesion

Mobile tumor

Extravasation

Primary breast cancer tumor

Figure 1-1: Schematic of the metastasis process. The metastatic cascade consists of
multiple steps that the primary tumor cells have to take in order to travel and grow
in the secondary site. Adapted from reference 19.

1.1.3.1

Brain Metastasis

Brain metastasis occurs when the primary tumor cells escape from their origin via
arterial circulation, extravasate across the capillary membrane of brain parenchyma and
finally seed and grow efficiently in the brain.[18] It is known that brain metastasis is the
primary reason for morbidity and mortality with 8.1% overall survival at two years.[20]
Brain metastases occur approximately in 20-40% adult patients with systemic
malignancies and the incidence is up to 10 times higher than primary malignant brain
tumors.[18,21,22] In the USA, it is expected that 21,651 to 43,301 new cases of brain
metastasis from any primary origin be diagnosed each year.[20] Nonetheless, the incidence
and prevalence of brain metastasis is rising.[22] The primary reason is prolonged survival
due to improved treatment outcomes of primary cancer. Some of monoclonal antibody
drugs such as Trastuzumab (Herceptin), which are effective for treating systemic
malignancies, cannot penetrate to the brain.[18,20] Moreover, advances in noninvasive
screening tools and modalities such as magnetic resonance imaging (MRI), have
contributed in detection of brain metastasis lesions.
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Breast cancer (20-30%) is the second most common source of brain metastases.
Other primary malignancies responsible for brain metastasis include: Lung cancer (4050%), melanoma (5-10%), lymphoma and other sites (4-6%).[18,23]

1.1.3.2

Brain Metastases Management

The treatment of patients diagnosed with brain metastasis remains clinically
challenging due to unique features of the brain. Un-treated brain metastasis causes
increased intracranial pressure, which results in median survival of only one month.[21,24]
The main treatment options for brain metastasis are surgery, radiation therapy (RT),
stereotactic radiosurgery (SRS) and corticosteroids (e.g. Dexamethasone). Chemotherapy
is not routinely used as the primary treatment modality for patients diagnosed with brain
metastasis.[21] Most of the treatments for these patients are considered to improve the
quality of life and achieve neurological palliation. The optimal selection of treatment
combination for brain metastasis relies on factors such as the anatomical location of the
lesion, number and size of the brain metastases, patient’s age, performance status, extent
of extracerebral tumor burden and histological features.[24]
Surgery is the treatment of choice if stringent conditions are satisfied. Surgery can
be performed only on accessible sites and depends on the general condition of the patient,
number and size of the metastasis.[20,21] Advances in neuro-oncology techniques have
enabled surgeons to resect both single and multiple lesions (2-4) with reduced risks of
post-operative complications.[24]
Radiation therapy (RT) is the most commonly used treatment modality for
patients diagnosed with brain metastases since the 1970s. The primary reason for this is
almost 50% of these patients have at least three metastases at the time of the diagnosis
ruling out surgery. Whole brain radiation therapy (WBRT) is valued for addressing both
macro and micrometastasis. Moreover, WBRT is an integral part of the adjuvant
treatment for patients with brain metastases following surgery.[24,25] WBRT is a common
fractionated external RT technique, in which the whole skull of the patients receives
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uniform radiation dose while sparing the eyes. The radiation absorbed in the tissue is
often represented as deposited energy per unit mass ([J/Kg]=Gy).[26] The most common
radiation dose/fractionation scheme for WBRT is 30 Gy delivered in 10 fractions over
two weeks. There is no agreement on the optimum radiation dose schedule/fractionation,
and the majority of clinical trials could not provide sufficient evidence of alternative
dosing schedules.[25,27] Acute radiation side effects such as alopecia (hair loss), dry
desquamation (skin peeling), excessive fatigue and transient neurological symptoms can
be seen in patients that receive WBRT. However, using steroids during RT may help with
these symptoms. Generally long-term and chronic RT complications in these patients are
not seen [27,28] as the median survival of patients treated with WBRT alone is estimated to
be 7 months,[20] but it has been reported that the response to the WBRT is related to the
primary histology of brain metastasis.[25]
Stereotactic Radiosurgery (SRS) is another RT method, which employs
collimated beams usually delivered in an arc around the tumor in a single or a small
number of fractions. Unlike WBRT technique, SRS delivers the radiation toward a lesion
identified on CT or MRI and spare the normal brain tissues by spreading low doses to a
large volume. It is a minimally invasive procedure and associated with high local control
rates (80-98% range).[24,28] Depending on the size of the tumor, radiation dose varies
between 18-24 Gy in one fraction. SRS is a better treatment option for preserving
neurocognitive function. However, SRS as the sole treatment has been advocated for
patients with small lesions (maximum size < 3 cm) and with 3 or fewer metastases in
their brain.[21,25,29] The overall survival of patients treated only with SRS has been
reported to be 7.5-12.5 months.[24]
WBRT is often used in combination with SRS. Retrospective studies have shown
that the combination of these two modalities may improve the overall survival in patients
diagnosed with brain metastases in the absence of extra-cranial progression.[24]
Chemotherapy is usually the last option for brain metastases patients. It is often
prescribed when the patient cannot undergo surgery and/or RT. Chemotherapy drugs can
also be used in combination with other treatments to suppress extracranial malignancies.
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One of the unique hurdles of treating tumors in the brain is the blood-brain barrier (BBB).
The tight junctions between brain endothelial cells control the passage of substrates from
the blood into the brain parenchyma. Thus, the penetration of the chemotherapeutic drugs
to the brain and their efficacy depend on their solubility, size and molecular
structure.[18,21]

1.1.4

Breast Cancer Metastasis
The primary reason for high mortality rate in patients initially diagnosed with

breast cancer is the metastasis. A substantial proportion of these patients (23.3%) develop
distant metastasis.[30] The molecular subtype of breast cancer appears to affect the pattern
of metastases. The probability of metastasis in the first five years after the breast cancer
diagnosis in TNBC subtype is higher than other histological subtypes. The common sites
for breast cancer metastases in order of prevalence are bone, liver, lung, brain and ovary.
[17,30,31]

The triple-negative subtype has the tendency to metastasize to distal organs

especially lung and brain.[32]
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Brain:
~10%
Lungs:
~20%
Liver:
~21%

Bones:
~42%

Figure 1-2: Breast cancer patients most commonly die from metastases instead of
primary tumor. The common distant sites for breast cancer metastasis are bones,
liver, lungs and brain. Main sites of metastasis in breast cancer patients and their
incidence are shown.[31] Adapted from reference 28 and by permission from
Macmillan Publishers Ltd: Nature Reviews Cancer, Nguyen et al. 9:274-284,
copyright© 2009 April Nature Publishing Group

1.1.4.1

Breast Cancer Brain Metastasis

Breast is the second common primary site associated with brain metastasis.[18]
With the advances in controlling primary breast tumor and systemic disease, the
treatment of breast cancer brain metastasis (BCBM) has become a crucial component for
improving the overall survival and quality of life in these patients.[33] It is estimated 10-
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30% of all breast cancer patients develop brain metastasis, which can either be
symptomatic or asymptomatic.[34,35] An average of 1-year survival can be seen in less
than 20% of breast cancer patients from the time of diagnosis with brain metastasis, and
approximately 50% of patients die because of the symptoms in their brain.[34,36,37] Breast
cancer subtype has been known to be an independent prognostic factor.
Among different subtypes of breast cancer, HER2 and TNBC have higher risk of
brain metastasis. Brain metastases occurs approximately in 10% of breast cancer patients
with triple-negative subtype.[34] Additionally, TNBC has the poorest overall survival rate
compared to the other subtypes, as this subtype does not benefit from systemic
treatments. [34,35,38]
The treatment options for patients with BCBM is the same as other histological
types of brain metastases.[34,39] Radiation therapy either as SRS or WBRT modality is an
inevitable part of the treatment for BCBM patients. The lack of effective treatment due to
the structure of the brain in addition to an increase in the incidence of brain metastasis
requires advancing our knowledge about current therapies. So far, improvements in
understanding breast cancer subtypes have led to the individualization of systemic
treatments, but as these subtypes reach the brain and form metastasis the same radiation
dose/fractionation is used. Not only the same radiation protocol is used for all subtypes of
breast cancer but all types of brain metastasis regardless of their primary origin. Often,
radiosensitivity of primary tumor is not taken into the account for radiation dose
prescription; this is despite the fact that brain metastases from breast cancer are relatively
more radiosetntisive than other primaries i.e. melanoma.[35,40] The question remains how
specific breast cancer subtype would respond to different doses of radiation.

1.1.5

Breast Cancer Brain Metastases Preclinical Models
Preclinical models of breast cancer brain metastases are important for

understanding the physiology of cancer and evaluating its response to treatment. For
most preclinical brain metastasis models, the cancer cells are directly injected into the

10

arterial circulation to imitate the metastatic process. This method requires developing cell
lines that grow preferentially in the brain when injected into the left ventricle of the
beating animal heart.[41] In this thesis we employed MDA-MB-231–BR, the brain tropic
human triple-negative breast cancer cell line. These cells are injected directly into the left
ventricle of the heart of female nude mice. The parental cell line (MDA-MB-231P) has
been passaged six times in brain metastases and in culture to establish brain seeking cells
(MDA-MB-231-BR).[42] This sub-line shares many characteristics of human brain
craniotomy samples such as apoptosis, proliferation and neuro-inflammatory response.[41]

1.2 Radiation Therapy
Radiation therapy can control rapidly dividing tumor cells (benign or malignant)
by creating breaks in their DNA (Deoxyribonucleic Acid). Ionizing radiation (IR) is often
considered as a “double-edged sword”, where it can induce mutations in the normal
healthy cells while eradicating tumor cell.[43]

1.2.1

Radiobiology Principles
When IR interacts with cells, it can damage organelles in the cytoplasm, cell

membrane and the DNA in the nucleus.[44] DNA is the central store of our genetic
information and an effective target for cell death.[45] DNA damage induced by IR can
result in cellular death or early steps of carcinogenesis depending on dose. Cell death can
be an active process through apoptosis (self-programmed death) or passive where cells go
through mitosis and manifest irreparable chromosomes.[26,44] Moreover, cells may
maintain their metabolic activity but lose their reproductive capacity (senescence).[46] On
the other hand, cells can repair the induced damage as they have an arsenal of repair
proteins. Radiation may induce cell cycle arrest, which gives the cells time to fix the
damage.[44,47] Normal mammalian cells can repair a substantial amount of DNA damage.
IR induces wide range of lesions to the DNA such as base damage, single-strand or
double-strand breaks.[46,48] These breaks can be induced either directly through ionization
and/or indirectly by transient production of free radicals through water radiolysis
process.[26,45]
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1.2.2

DNA Double-Stranded Breaks (DSBs)
DNA double strand-breaks (DSBs) can be induced by an endogenous source, for

example products of internal metabolism, or exogenously such as IR. DNA DSBs are the
most biologically significant effect of ionizing radiation. It is known that exposure to 1
Gy of IR (photon) produces approximately 30-40 DNA DSBs in diploid mammalian
cells.[45,46,48] DSBs are lesions formed when two opposite strands of the DNA duplex are
broken in a distance less than ten base pairs.[45] The incidence of DSBs is relatively rare
compared to other types of DNA damage, but the repair mechanism is more complex. In
normal mammalian cells, it takes more than 50 minutes to repair 50% of DSBs after
induction, whereas for other DNA damages such as base damage or single-strand break
the repair will be achieved in less than 20 minutes.[47] Following DSBs a cell can take
two different pathways to repair the break depending on its status in the cell cycle.[49]

1.2.2.1

DSBs Detection Techniques

Assessment and quantification of cellular DNA damage is crucial in cancer
treatments.[50] There have been many techniques developed for detecting DNA DSBs,
some of which, such as conventional “halo assay” have been replaced by other assays.[47]
Pulsed field electrophoresis (PFGE) and comet assay are two methods that can measure
the physical fragmentation of the DNA after the break for both single and double-strand
breaks.[51,52] These techniques use liberated DNA from lysed cells and require radiation
dose of >5Gy for a reliable assessment.[47,51,52] In late 1990’s Bonner and Löbrich
introduced the γ-H2AX technique to monitor the induction and repair of DSB.[53,54]
Gamma histone 2AX (γ-H2AX) technique is 100 times more sensitive and precise than
the other methods and allows investigation of the temporal and spatial induction of DNA
DSBs in intact cells and tissue samples. γ-H2AX can be used to detect doses as low as
1.2 mGy.[45,55] It has been shown that each γ-H2AX focus represents one DSB and
consists of hundreds to thousands phosphorylated histone H2AX.[54,56] A primary
antibody against γ-H2AX is used in combination with a secondary fluorescent tag to
visualize these foci in a typical immunohistochemistry procedure. Figure 1-3
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demonstrates an example of our immunofluorescence staining of γ-H2AX to detect DNA
DSB visualized under a confocal microscope. This assay has been employed for a
number of applications in diagnosis and assessment of treatment efficacy of cancer.[57,58]
γ-H2AX has also been an attractive in-vivo biomarker for detection of malignant cells in
blood samples and biopsies.[58,59] It has been shown that tumors and premalignant lesions
demonstrate high amount of endogenous γ-H2AX due to replication stress, dysfunctional
telomeres and genomic instability.[55,60–62] However, one of the caveats of this method is,
it does not detect the actual physical break of the DNA, but the cellular activities
following the damage. The timing of γ-H2AX foci loss does not precisely agree with the
final rejoining of the DNA DSB leading to possible inconsistencies.[63,64]

Figure 1-3: Image of mouse brain tissue 30 minutes after receiving ~1 Gy, stained
with fluorescent anti-γ-H2AX antibody. The arrow is pointing to a focus (red),
which represents a DNA DSB. Blue is DAPI counterstain for the nuclei.
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1.2.2.2

Role of γ-H2AX

DNA damage happens in the context of chromatin.[47,58] Chromatin structure
consists of DNA and proteins. The fundamental units of chromatin are called
nucleosomes. Approximately 145-147 DNA base pairs wrap around four pairs (an
octamer) of histone proteins (H2A, H2B, H3 and H4) to form a nucleosome.[65]
Following DNA DSBs from IR, the cell senses the damage via ATM (Ataxia
telangiectasia mutated), a member of the phosphoinositide 3-kinase-related-kinase
(PIKK) family.[66] As a result, the histone variant H2A, H2AX (~10% of H2A), are
rapidly phosphorylated in the vicinity of the DSB and the chromatin around the break.[63]
The phosphorylated H2AX is termed γ-H2AX. Figure 1-4 demonstrates the cascade of
activation of H2AX. Phosphorylation of H2AX is also controlled by other PIKK
members such as ATR (ATM- and Rad3-related) and DNA-PKcs (DNA-dependent
protein kinase catalytic subunit).[66] However, it is mostly ATM that governs the
phosphorylation of H2AX following DNA DSB.[63] γ-H2AX serves as a beacon for the
cell and triggers DNA damage response (DDR), recruiting detection, signaling and repair
proteins to the DSB site.[49] For each DSB, hundreds to thousands of nearby H2AX
molecules get phosphorylated to form a focus.[54,63] The number of foci is known to
correlate linearly with IR dose in most cell types.[61,67] However, at high radiation doses
such as 2 Gy, detecting individual focus shortly after IR (~30 minutes) is not possible due
to overlapping foci and diffuse covering of γ-H2AX in tumor nuclei.[54,68,69] Counting
discrete foci either manually or automatically on 3D images acquired from confocal
microscopy is the common technique employed for low doses of radiation.[61,70] At higher
radiation doses where finding separate foci is challenging, intensity quantification
techniques such as flow cytometry in cells or image intensity from fluorescence-stained
tissue samples are commonly used.[68–71] It should be noted that γ-H2AX is a time
sensitive marker. The phosphorylation of H2AX starts within 3 minutes after IR and gets
to the maximum level approximately 30 minutes after IR exposure.[53–55] As DNA DSBs
are repaired, γ-H2AX either gets dephosphorylated or removed from the chromatin.
[56,61,63]

Resolving γ-H2AX over time allows us to assess DNA repair kinetics and

mechanism of action.
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Figure 1-4: DNA is wrapped around core histone proteins. Upon DNA doublestrand break, one of the histone proteins, H2AX, gets rapidly phosphorylated by
ATM adjacent to the site of damage. The phosphorylated H2AX is termed γ-H2AX.

1.2.3

Radiation Therapy Dose-Response Relationship
One of the concerns in clinical radiobiology is the response of tumor and normal

tissue to radiation doses. A sigmoid radiation dose-response curve has been considered
for both tumor control and normal tissue complications.[26,46,72] In this relation, the
response to radiation tends toward zero as dose approaches zero and tends toward 100%
for large radiation doses.[26,45] The response of tumors to radiation can be measured by
different end-points such as local tumor control and tumor regrowth delay.
While same radiation dose/fractionation is prescribed for the treatment of all brain
metastasis, patients outcomes are different depending on the origin of the tumor.[40,73,74] A
major factor is that tumors from different origins have different radiosensitivity and
steepness of the dose-response curve. Inter and intra-patient tumor heterogeneity are also
found within one type of cancer.[75] These differences can be partly explained by
dissimilarities in growth kinetics, loss of apoptotic or checkpoint genes, DNA damage
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and repair pattern and the microenvironment influenced by hypoxia and angiogenesis.[45]
All of these factors play a crucial role in determining the response of the tumors to RT.
In-vivo dose-response studies in preclinical models have the advantage of both
inherent tumor radiosensitivity and also the influence of the tumor’s microenvironment.
To be able to design experiments using human cancer cell lines in an animal model that
can recapitulate clinical dose-response challenges, simulating clinical scenarios in the lab
plays a key role.[76] To deliver clinically relevant radiation doses, biological effective
dose (BED) formula helps to convert the clinical dose/fractionation regimen to practical
dose/fractionation on the models while having the same biological effect.[77,78] BED is a
measure of the biological dose delivered by the specific total dose and fractionation:
𝑩𝑬𝑫 = 𝒏𝒅  [  𝟏 +    𝒅

𝜶
𝜷

  

  ],

Where n is the number of fractions, d is the dose per fraction and

(1-1)

!
!

is a radiosensitivity

parameter of the tissue.[45,79]

1.2.4

Preclinical Radiation Therapy Devices
To be able to investigate and validate some of the clinical and technological

evolutions in the field of cancer and radiation therapy, radiation delivery units are needed
for preclinical models. These devices enable us to mimic human radiotherapy conditions.
For many decades, small animal models received radiation using Cs137 or Co60 irradiator
boxes or clinical linear accelerators. Improvements in technology and the need for precise
and accurate dose delivery motivated investigators to design and build imaging and
radiation therapy devices dedicated to preclinical studies. Nowadays, preclinical
machines capable of on-board imaging along with a range of beam energies (kV)
appropriate for the size of small animals are available.[80]
Many groups have developed sophisticated research systems for precise small
animal radiation. These machines such as SARRP (John Hopkins), X-rad 225Cx

16

(Princess Margaret Hospital) and modified micro-CT/RT scanner (Stanford University
and University of Western Ontario) are the most commonly used devices in this
field.[80,81]
Modified Micro-CT/RT scanner has the advantage of high-quality on-board
imaging, computerized asymmetric collimator and live animal monitoring.[81] On-board
imaging refers to the imaging unit that is installed on the treatment machine and allows
imaging before treatment to confirm a match between treatment and planned setup. The
combination of image guidance and asymmetric collimators allow irradiating small subregional fields in three-dimensions. This unit has been used to study the effect of
radiation therapy on normal tissues and will be employed in this thesis for our tumor
model.[82]
Precision and accuracy are significant factors in small animal radiation therapy.
For instance, the width of the mouse brain is approximately 1 cm in its largest dimension,
and sub-millimeter precision is required to irradiate sub-regions of the brain. Considering
the scale of animal models, error margins should be less than 0.2 mm to deliver a precise
conformal dose.[83] Accurate set-up and immobilization, help with precise radiation dose
delivery.[84] In the clinical setting, external stabilization devices such as head holder, bite
blocks and thermoplastics are often used specifically for head and neck cases to minimize
the patient’s movement and maximize the reproducibility of the treatment set-up.[85] In
preclinical setting, restrainer devices are needed to position the animal in the desirable
setting while maintaining animal’s body temperature and monitoring it during radiation
dose delivery.

1.3 Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) is currently the standard imaging modality for
detecting brain metastasis, radiation treatment planning and follow-up in patients. It has
greater sensitivity in comparison with contrast enhanced CT for detecting small brain
lesions.[22] MRI is a noninvasive imaging technique, which requires no IR and results in
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high soft-tissue contrast. Gadolinium-DTPA (Gd) is the common contrast agent for
detecting brain lesions.[86] In patients with brain metastases, this agent can penetrate leaky
and disrupted tumor-brain barriers, resulting in tumors with hyper-intensities.[87]
In brain metastases preclinical models, 3D MRI allows monitoring tumors
temporally and spatially.[88,89] More specifically, this imaging modality is useful in
assessing tumor volume and morphology before and after radiation to investigate the
effect of treatment.[90] Sequential MR images followed by histological analysis are used
in this thesis to investigate response of the tumors to the radiation at the small animal and
cellular level.

1.3.1

Balanced Steady State Free Precession (bSSFP) MRI
Sequence
The balanced steady state free precession (bSSFP) MRI sequence was primarily

used for cardiac imaging but recently has been employed to image other sites.[91,92] The
most important feature of this sequence is its ability to produce high-resolution images
while keeping high signal-to-noise ratio in a reasonable scan time. The contrast in bSSFP
is dependent on the ratio of tissue T2 relaxation rate to its T1 relaxation rate. This ratio
means that in this sequence images of fat and fluid, which have different T1 and T2
relaxation time but have the same ratio of T2/T1, appear as bright regions.[91,92]
The utility of the bSSFP sequence in the imaging of preclinical models and brain
metastasis has been explored over the past few years.[93–95] A large fraction of brain
metastases are not permeable to Gd at early time-points and would not optimally be
imaged with T1 or T2 post-contrast sequences. Percy et al. have shown that pre-contrast
bSSFP can detect brain metastasis regardless of their permeability status and is a
sensitive sequence to be used for brain metastases in preclinical models.[88,96] In this
thesis, bSSFP MRI sequence will be used to evaluate the response of brain metastases to
radiation longitudinally.
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1.4

Three-Dimensional (3D) Printing Technology

Three-dimensional (3D) printing is rapidly being developed and adopted. This
technology allows building tangible 3D solid objects from virtual designs. There are
three main steps to fabricate the desirable object: 1) Modeling 2) Printing 3) Processing.
Manual 3D modeling is usually done using computer aided design (CAD) (e.g.
AutoCad® and SolidWorks™). The drawing will be exported as Stereolithography
(.STL) file format to be readable by the printer. The printer software interprets the .STL
model to thin cross-sectional layers. The 3D-printer used in this thesis is Object30 Pro, an
acrylic based plastic printer. It lays down thin horizontal layers (28 microns) of liquid
resin, which would be cured by ultraviolet light. The layers will be fused together
automatically and create the final object. The processing step consists of smoothing the
surface of the object with sand paper and using a water jet to remove the residual
material. Figure 1-5 shows the processes involved in 3D-printing. We will be using 3Dprinting technology in our small animal brain irradiation studies.
Three-dimensional printing technology brings benefits over the conventional
manufacturing method. It can be used to create customized objects with varying
complexities from virtual designs in an inexpensive and timely manner. This technology
has been used in various sectors such as industry, medicine, forensic science and
education and will have a great influence on many fields in the near future.[97]
Interestingly, this technology has found its way to preclinical laboratories to construct
objects needed for experimental designs.[98,99] Furthermore, the nature of the digital file
offers new prospects for sharing and collaborating with researchers. This allows printing
the same devices and/or modifying the existing design to suit the experimental setting.
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3D-model in AutoCad®

Object30 Pro printer

3D-printed object

Figure 1-5: Processes involved in 3D-printing. Modeling is done in AutoCAD and
exported as .STL format. The 3D-printer converts the digital file to thin crosssectional layers. The final 3D-printed object is shown on the 3D-printer tray. A final
processing step is needed to remove residual material from the object.

1.5 Thesis Objectives and Outline
The main goal of this thesis is to quantify the response of breast cancer brain
metastasis to different radiation doses. To achieve this, we had two specific objectives:
1. To improve and histologically evaluate radiation targeting accuracy for mouse
hemi-brain radiation therapy on the micro-CT/RT unit.
2. To quantify the acute amount of induced DSBs in a breast cancer brain
metastasis model for different radiation doses and evaluate dose-response in
the brain metastasis model longitudinally after treatment.

Objective 1 is addressed in Chapter 2 where we utilized 3D-printing technology
for animal immobilization, enabling studies in objective 2. We designed a mouse
restrainer for the purpose of half-brain radiation and used 3D-printer for the fabrication.
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The device was evaluated for targeting accuracy using immunohistochemistry. This
work has been submitted to the journal of Medical Physics.
Chapter 3 discusses the response of breast cancer brain metastases to different
radiation doses utilizing our 3D-printed device. The amount of induced (acute) and
residual (longitudinal) DNA double-strand breaks was quantified for both tumor and
mouse normal brain cells. bSSFP MR imaging was used to determine the in-vivo
response of tumors in the mouse model following hemi-brain radiation. A manuscript
based on this chapter is in preparation.
In chapter 4, major findings of this thesis are summarized. This chapter discusses
the limitations of the present study and future investigations are proposed.
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Chapter 2

2 Immunohistochemical Evaluation of Mouse Brain Irradiation
Targeting Accuracy with 3D-Printed Immobilization Device
This chapter is adapted from the technical note, “Immunohistochemical
evaluation of mouse brain irradiation targeting accuracy with 3D-printed immobilization
device” under review in Journal of Medical Physics, by Zarghami N, Jensen MD, Talluri
S, Foster PJ, Chambers AF, Dick FA and Wong E.

2.1 Introduction
More than 50 percent of cancer patients receive IR as a main part of their
treatment.[1] Over the last few decades, sophisticated and computerized treatment
planning, dose delivery and on-board imaging systems have been introduced and are used
routinely. The biological responses of tumor and normal tissue to radiation therapy can be
investigated using animal models. Accurate simulation of the patient’s treatment scenario
on small animals in laboratories will facilitate translating experimental results to the
clinical setting and help further our understanding of radiobiology.
Many groups have developed sophisticated preclinical radiation devices, which
are capable of treating sub-regional fields using technologies such as on-board cone beam
CT (CBCT). Some devices have integrated bioluminescence tomography while others
computerized collimators.[2–5] Indeed, these cutting-edge devices have enabled
researchers to investigate some of the current radiobiological challenges and deliver more
complex dose distribution. However, another challenge for accurate radiation dose
delivery on live animals is their set-up and positioning. While accuracies for radiotherapy
in the clinical settings have been elucidated[6], analogous specifications for small animals
are not yet available. Radiation treatment is commonly performed on sedated animals, but
unconstrained anatomical structures complicate positioning and restraining devices are
needed for accurate targeting.
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Several groups have developed stereotactic holders to improve dose delivery.[7–9]
Moreover, sophisticated commercial devices are available for different small-animal
imaging machines.[10] While all these stereotactic holders have the same purpose of
improving animal positioning, they may lack some features for some small animal
radiotherapy treatment situations. Such features may include physiological monitoring,
animal warming, and the capability for fine position adjustments. Commercially available
devices have tended to be designed for imaging rather than radiotherapy. More
importantly, traditional fabrication methods may not be economical, especially if several
customized variations of a stereotactic holder are required. To allow investigators to
optimally position the animal for each treatment site and minimize trauma, it is desirable
to economically fabricate multiple external holders for small animal radiation therapy.
In this technical note, we introduce a completely 3-dimensional (3D) printed
mouse head holder for a micro-CT/RT system. We investigate the feasibility of using 3D
printing technology to make a head holder and then evaluate the head holder’s capability
for precise mouse brain irradiation. The targeting accuracy is verified with half brain
irradiation, using fluorescent immunohistochemical staining for phosphorylated histone
H2AX, γ-H2AX, a marker for DNA double-strand breaks[11][12], on frozen mouse brain
sections. γ-H2AX is a sensitive bio-dosimeter and can detect radiation doses as low as
1.2mGy.[13] This novel device demonstrates the potential application of 3D-printing to
small animal experimental platforms.

2.2 Methods and Materials
2.2.1 Head Holder Design and 3D-Printing
The stereotactic mouse head holder was designed for the GE eXplore CT 120 (GE
Healthcare, Milwaukee, WI, USA) preclinical imaging system rat couch. This unit has
been modified to be capable of small animal imaging and irradiation with on-line image
guidance and multiple collimated irradiation fields.[2]
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To size the stereotactic holder, mouse gross anatomical measurements were done
on 6-8 week old C57BL/6 and NU-Foxn1nu (Charles River Laboratories, Wilmington,
MA) mice. The mouse head holder was designed using AutoCADTM 2014 (Autodesk,
lnc. San Rafael, CA, USA) (Figure 2-1a). The head holder design has integrated
anesthesia gas delivery and respiration pillow sensor. The nose cone position can be
adjusted according to the size of the mouse snout and connects to a commercially
available Mapleson-D (Patterson Scientific, USA) for anesthetic gas. The respiration
pillow sensor is placed under the abdomen of the animal and its rate can be monitored
during the procedure. The mouse incisors are placed in a bite bar inside of the nose cone.
The bite bar and two length-adjustable ear bars immobilize and orient the head in the
desired position. The 5° inclined bed allows the mouse to be in a neutral position while
keeping the head level with the axis of gantry rotation. There are indents for all four paws
and the tail of the animal to ensure reproducible set-up. A separate hot water circulation
is wrapped around animal’s body to maintain its body temperature.
The drawing was exported as three separate parts: bed body, nose cone and bite
bar. The stereolithography (.STL) format was imported to ObjectStudio Software
(Stratasys, Inc. Rehovot, Israel) to convert the drawing to 3D layer modeling. The
fabrication was done with Objet30Pro printer (Stratasys Inc. Rehovot, Israel), using an
ultraviolet cured, acrylic based plastic (Verowhite Plus). The head holder was postprocessed with a water jet to remove excessive supporting materials and the holes were
threaded for screws (Figure 2-1b).
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Figure 2-1: 3D-printed mouse head holder. a. Conceptual view of the head holder
design in AutoCAD™ b. Photograph of 3D-printed holder with integrated
respiratory monitoring pillow and adjustable nose cone, tooth bar and ear bars c.
Mouse setup in head holder. A water blanket is used on top of the animal for
thermal maintenance. A CT small ball bearing (BB) marker was placed on the right
side of the head holder to help the user with the animal orientation on CT and
fluoroscopy.

2.2.2 Mouse Brain Irradiation
All procedures followed animal care protocols approved by the Animal Use
Subcommittee of The University of Western Ontario and were consistent with the
policies of the Canadian Council on Animal Care (Appendix A: Animal Use Protocol).
Mice were anesthetized using 1.5 to 2% vaporized inhaled isoflurane while held in the
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3D-printed head holder (Figure 2-1c). Animals were placed in a feet first prone position
inside the scanner. To validate targeting accuracy, the right half of brains from 10 adult
mice (C57BL/6 or NU-Foxn1nu) received the minimum dose of 16 Gy in a single
fraction. Longitudinal fissure (LF) was determined as the anatomical target for the edge
of the radiation field within the brain. Setup lasers were initially used to set the scanner
landmark position relative to the head holder. CT images were used to verify the position
of the ear bars and tooth bar (Figure 2-2a, b). Moreover, CT was used to check the mouse
head alignment in 3D. Once the mouse was positioned for treatment, online dorsalventral fluoroscopy was acquired to identify the skull features and position the
collimators. The collimators were moved so the animal body and left hemisphere of the
brain were shielded. The right half of the brain was irradiated with a single field (14x20
mm2) from the animal’s ventral-dorsal direction (Figure 2-3).

Figure 2-2: Pre-treatment CT images of the mouse brain positioned in 3D-printed
head holder. a. Coronal view b. Sagittal view
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Figure 2-3: Beam’s eye view fluoroscopy image of the mouse from the top (dorsalventral view). Animal is positioned prone in the 3D-printed head holder. The
collimated radiation field (14x20 mm2) is fused on top of the open field.

2.2.3 Immunohistochemistry
Mice were perfused with 0.9% saline containing 4% paraformaldehyde (PFA)
approximately 30 minutes after treatment. Brains were harvested and post-fixed in 4%
PFA followed by placing them in successive sucrose solution (10-30%) until the
specimen sank to the bottom.[14] Brain samples were embedded in Tissue-Tek OCT
Compound (Sakura, Torrance, CA) and frozen. Cyrosectioning of coronal slices was
performed with 10-µm slice thickness. Sections were stained for fluorescent γH2AX
using a well-established protocol published by Ford et al.[14]. Sections were stained with
mouse anti-γ-H2AX antibody (anti-phospho-histone H2AX, Ser139, clone JBW301;
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Millipore, Billerica, MA, USA). DNA counterstaining was achieved with incubation in
DAPI (4', 6-diamidino-2-phenylindole, Vector Laboratories, Inc. Burlingame, CA). A
motorized fluorescence-scanning microscope (Leica Inc.) was used to automatically
acquire images with a 10X objective and stitch them together to form whole brain images
on stained histology sections of 5 mice. To quantify targeting accuracy, another set of
10X images, focusing on the midbrain region was acquired with a fluorescence
microscope (Carl Zeiss Canada Ltd) for all 10 mice. All images were acquired under the
same microscope settings and exposure parameters.

2.2.4 Analysis
Visualization of the actual beam in tissue was possible using γ-H2AX staining on
ex-vivo brain sections. For targeting accuracy, we measured the distance from the edge of
the radiation beam to the intended target (longitudinal fissure) using the digital readout of
the fluorescent microscope (Figure 2-4 e). The edge of the radiation field was visually
defined as the border separating cells having enhanced levels of γ-H2AX from those with
background staining. The beam offset was measured on two separate histology samples
for 8 of 10 mice, and only on one section from the remaining two mice (Figure 2-4 a-d).
To measure the tilt of the animal’s head around the rostral-caudal axis, the angle between
longitudinal fissure and the γ-H2AX radiation border was determined on whole brain
images in 5 mice.
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Figure 2-4: Fluorescence microscopy of γ-H2AX stained brain sections (red), imaged
at 10X magnification. DAPI counterstaining of DNA is shown in blue. Sections from
four irradiated mice treated in 3D-printed head holder are shown. Intended target
was the right half of the brain. (a-d) Example measurement of targeting error on
zoomed 10X image. Distance between longitudinal fissure (white line) and γ-H2AX
field edge is shown (e).

2.3 Results
2.3.1 Mouse Set-up in 3D-printed Head Holder
Mice were under anesthesia for approximately two hours and breathing rate was
monitored during treatment. Mice recovered well from isoflurane after treatment without
any signs of trauma to their ears or mouth.

2.3.2 Validating Beam Targeting Accuracy with γ-H2AX Staining
Immunohistochemical staining of brain sections stained for γ-H2AX showed
precise targeting of the field edge at the expected location. The sharp and straight edge of
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the field through the whole brain for all samples indicates a stable and straight head
position around the axis of gantry rotation. The edge of the beam was offset from the
longitudinal fissure by a mean distance of 146 ± 98µm (standard deviation) towards the
left side in 10 mice. The average head tilt was determined to be 1.21 ± 1° (standard
deviation) about the axis of the gantry rotation (rostral-caudal), indicating the x-ray
source was positioned slightly towards the right side of the animal (Table 2-1).

Table 2-1: Targeting accuracy measurement of γ-H2AX stained brain sections.
Positive angle indicates an x-ray tube towards the right side of the mouse. Positive
offset indicates the radiation beam towards the left side of the longitudinal fissure.
Mouse

Tilt angle
(degree)

Offset
Measurement1
(µm)

Offset
Measurement2
(µm)

Offset Mean
(µm)

1

1.5

241

211

226

2

0.2

32

26

29

3

2.3

172

190

181

4

N/A

168

191

180

5

0.1

21

48

35

6

N/A

69

52

61

7

N/A

178

200

189

8

N/A

255

N/A

255

9

2.0

280

N/A

280

10

N/A

34

28

31

N/A indicates not available.
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2.4 Discussion
We designed, implemented and verified a 3D-printed mouse head holder. With
image guidance and the head holder, we found the radiation beam edge could be located
within 0.15 mm of the intended target as determined by γ-H2AX immunohistochemical
staining of mouse brain sections.
The 3D-printed head holder contains many of the desired features. Its fabrication
is more economical than commercial versions and allows for modification according to
specific experimental set-ups.
One possible limitation of 3D-printing is the strength of the material. To
overcome the fragility of the material, the base of the head holder was designed thicker
(1.5cm) compared to the other parts. Presence of the bed or ear bars in the path of the xray beam may interfere with dose delivery from lateral and ventral directions; therefore a
different design may be needed for treating from other directions.
We validated our targeting accuracy by doing immunohistochemical staining of
our samples. Physical changes such as tissue shrinkage and changes in morphology are
possible during tissue processing. Wehrl et al. [15] measured shrinkage between -11.7% to
30.7% for the PFA fixative depending on the anatomical landmark. Moreover, Ford et
al.[14] reported a shrinkage factor of 0.85 for fixed and frozen mouse brain samples.
Applying the 0.85 shrinkage factor to our data, the mean beam offset is 172 ± 115µm.
The 3D-printed head holder assisted with animal positioning, however the beam
offset from the target not only depends on the mouse head alignment, but also on the
placement of the collimators. In this study, the half brain was determined visually using
on-board imaging. Moreover, the 20%-80% radiation penumbra for 14x20 mm2 field is
estimated to be 0.57-0.73mm for this system.[2] All histological analyses were done on
10X microscope images, which is not suitable for detecting γ-H2AX foci in response to
small doses. Only the sharp edge of the beam was detected and the localization may be
dependent on microscope and display parameters.
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Our designed 3D-printed mouse head holder may not only be applicable to mouse
brain irradiation but potentially to other sites. With modification in design, our head
holder may be a starting point for an even greater range of imaging and radiation
preclinical studies.

2.5 Conclusions
Numerous studies have employed different stereotactic devices. We have
demonstrated that a 3D-printed stereotactic head restraint can allow accurate and precise
irradiation in a mouse brain. Immunohistochemical γ-H2AX staining validated the
irradiation of specific sub-regions of the mouse brain with less than a millimeter error.
Fast 3D-printing technology allowed us to produce a custom stereotactic holder with the
necessary features for our study in an economical and timely manner.

2.6 Acknowledgment
We would like to thank John Moore for assistance in operating the 3D-printer.
Frank Van Sas and Brian Dalrymple are acknowledged for assistance with post-printing
fabrication. We thank Tom Hrinivich for helpful discussions and Heather Craig for
assistance with the motorized microscope. This work is funded by the Natural Sciences
and Engineering Research Council of Canada and London Regional Cancer Program
Catalyst Grant and also supported by a Translational Breast Cancer Studentship award to
NZ funded in part by the Breast Cancer Society of Canada.

42

2.7 References
1.

DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al.
Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin
2014;64(4):252–71.

2.

Jensen MD, Hrinivich WT, Jung J a, Holdsworth DW, Drangova M, Chen J, et al.
Implementation and commissioning of an integrated micro-CT⁄RT system with
computerized independent jaw collimation. Med Phys 2013;40(8):0817061–
08170613.

3.

Tuli R, Armour M, Surmak a., Reyes J, Wong J. Abstract 5725: Accuracy of offline bioluminescence imaging to localize targets in pre-clinical radiation research.
Cancer Res 2012;72(4):5725–5725.

4.

Van Hoof SJ, Granton P V., Verhaegen F. Development and validation of a
treatment planning system for small animal radiotherapy: SmART-Plan. Radiother
Oncol 2013;109(3):361–6.

5.

Clarkson R, Lindsay PE, Ansell S, Wilson G, Jelveh S, Hill RP, et al.
Characterization of image quality and image-guidance performance of a preclinical
microirradiator. Med Phys 2011;38(2):845–56.

6.

Dyk J Van, Battista JJ, Bauman GS. Accuracy and Uncertainty Considerations in
Modern Radiation Oncology.

7.

Baumann BC, Benci JL, Santoiemma PP, Chandrasekaran S, Hollander AB, Kao
GD, et al. An Integrated Method for Reproducible and Accurate Image-Guided
Stereotactic Cranial Irradiation of Brain Tumors Using the Small Animal
Radiation Research Platform. Transl Oncol 2012;5(4):230–7.

8.

Zhang L, Yuan H, Burk LM, Inscoe CR, Hadsell MJ, Chtcheprov P, et al. Imageguided microbeam irradiation to brain tumour bearing mice using a carbon
nanotube x-ray source array. Phys Med Biol 2014;59(5):1283–303.

43

9.

Kiehl EL, Stojadinovic S, Malinowski KT, Limbrick D, Jost SC, Garbow JR, et al.
Feasibility of small animal cranial irradiation with the microRT system. Med Phys
2008;35(10):4735–43.

10.

Holdsworth DW, Detombe S a., Chiodo C, Fricke ST, Drangova M.
Implementation and assessment of an animal management system for small-animal
micro-CT / micro-SPECT imaging David. Proc SPIE 2011;7965:79650N –
79650N – 6.

11.

Pilch DR, Sedelnikova O a, Redon C, Celeste A, Nussenzweig A, Bonner WM.
Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem
Cell Biol 2003;81:123–9.

12.

Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA Double-stranded
Breaks Induce Histone H2AX Phosphorylation on Serine 139. J Biol Chem
1998;273(10):5858–68.

13.

Rothkamm K, Löbrich M. Evidence for a lack of DNA double-strand break repair
in human cells exposed to very low x-ray doses. Proc Natl Acad Sci U S A
2003;100(9):5057–62.

14.

Ford EC, Achantac P, Purgerc D, Armoura M, Reyesa J, J. Fonga L, et al.
Localized CT-Guided Irradiation Inhibits Neurogenesis in Specific Regions of the
Adult Mouse Brain. 2012;175(6):774–83.

15.

Wehrl HF, Bezrukov I, Wiehr S, Lehnhoff M, Fuchs K, Mannheim JG, et al.
Assessment of murine brain tissue shrinkage caused by different histological
fixatives using magnetic resonance and computed tomography imaging. Histol
Histopathol 2015;30(5):601–13.

44

Chapter 3

3

Evaluation of Radiation-Induced DNA Double-Stranded
Breaks and Tumor Response in a Breast Cancer Brain
Metastasis Model
This chapter is adapted from the manuscript entitled “ Evaluation of radiation-

induced DNA double-stranded breaks and tumor response in a breast cancer brain
metastasis model”. This research manuscript is in preparation and will be submitted to the
International Journal of Radiation Oncology * Biology * Physics for publication. The
authors of this manuscript are Zarghami N, Murrell DH, Jensen MD, Dick FA, Chambers
AF, Foster PJ and Wong E.

3.1 Introduction
The improvement in survival rates in majority of primary cancers has led to an
increase in the prevalence of brain metastasis. Each year, brain metastases are detected
three to ten times more frequent than newly diagnosed primary malignant brain tumors,
i.e. gliomas.[1–3] The median survival of patients from the advent of brain metastasis is
poor.[4] Brain metastasis is associated with various types of disseminated cancer. The
major primary sites include lung (40%-50%), breast (15%-25%) and melanoma (5%20%).[5–7] The unique micro-environmental structure of the brain often results in
therapeutic failure with chemotherapy. Furthermore, brain is usually the last site of
metastasis, after metastases to other visceral organs. Therefore, management of the brain
metastasis is considered to be mainly palliative. Multiple brain metastases are often
treated with the radiation dose of 30 Gy in 10 fractions using whole brain radiation
therapy technique.[8,9] Typically, patients with 1-3 lesions (each < 3 cm) are eligible for
stereotactic radiation therapy alone or in combination with whole brain radiation
therapy.[7] The dose for stereotactic radiation of brain metastases varies, but most
common prescription is 18-24 Gy in one fraction. While ionizing radiation (IR) is the
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mainstay of treatment for these patients, in practice only one radiation scheme and
schedule, such as described above, is employed for the treatment of all brain
metastases.[1,9,10] That is, despite the fact that the response of brain metastases to radiation
therapy has been shown to depend on the type of primary tumor [11,12], the same radiation
scheme is prescribed for all brain metastasis.[13]
The brain is a common metastasis site in breast cancer following bone and
visceral organs. However, advances in adjuvant and chemotherapy drugs coupled with
new sensitive imaging techniques have improved the control of extra-cranial diseases and
unmasked brain metastasis as one of the late events in advanced breast cancer patients.[14]
The incidence of brain metastases in HER2+ and triple-negative is higher in comparison
to other breast cancer subtypes.[15,16] Patients with tripe-negative breast cancer are
typically at higher risk of CNS relapse and have the poorest overall survival compared to
other types as the treatment options are limited for this group.[17] Brain lesions from
breast cancer are heterogeneous. This heterogeneity is also reflected in their response to
the treatment.[18] Since the treatment for primary breast cancer is becoming more
efficacious, the management of the metastasis from this disease should be re-examined.
Understanding the response of breast cancer brain metastases to different radiation doses
is essential for improving our knowledge and ultimately radiation dose prescription in
clinics. Using sophisticated preclinical radiation therapy devices, imaging techniques and
biological markers on breast cancer brain metastasis models, we are presented with a
unique opportunity to reassess these fundamental yet critical radiobiology questions.
Radiotherapy relies on IR-induced DNA damage to control tumor cell division.
DNA double-strand breaks (DSBs), are known to be lethal lesions that are responsible for
the mitotic death from radiation.[19] In response to IR-induced DSBs, histones H2A
variant, H2AX, are rapidly phosphorylated to form γ-H2AX.[20] γ-H2AX marker can be
employed as an indirect measurement of DNA DSBs.[21] It has been known that tumors
have higher amount of “cryptogenic” γ-H2AX due to endogenous sources such as
replication stress, genomic instability and uncapped telomeres compared to the healthy
tissue.

[22–24]

Timing is critical for γ-H2AX detection, as it decays over time. The time

period of 30 to 60 minutes post exposure is often known to give reliable and maximal
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scoring for radiation-induced damage.[21] Depending on time-point after radiation
exposure, γ-H2AX may also provide valuable information regarding DNA damage and
repair kinetics. This technique has been used as a tool to predict the response to radiation
and estimate the side effects in normal tissue after treatment.[25,26] Studies have
investigated the residual γ-H2AX of murine tissues from days to two months after
exposure to detect radiation-induced toxicity such as fibrosis and myelopathy.[27–29] These
data prove the presence of DNA DSBs in some normal tissues long time after IR. To the
best of our knowledge, no evaluation of residual γ-H2AX radiation response in breast
cancer brain metastases has previously been examined.
The aim of this study was to evaluate the dose-response of human triple-negative
breast cancer brain metastases to radiation, by irradiating half brain of MDA-MB-231-BR
mouse model with various radiation doses. We assessed biological and morphological
changes in tumors after radiation treatment. The histological radiation response was
evaluated at two time points: 1) Acute (30 minutes after RT) and 2) Longitudinal (11
days after RT). Mice were also imaged with balanced steady state free precession
(bSSFP) MR sequence before radiation therapy and 11 days after treatment. Changes in
the volume of tumors were analyzed using MRI.

3.2 Material and Methods
3.2.1 Cell Culture
For this study, the brain tropic human triple-negative breast cancer cell line,
MDA-MB-231-BR, stably transfected with enhanced green fluorescent protein (EGFP)
was used.[30] Cells were cultured and maintained in Dulbecco’s modified eagle’s medium
(DMEM) containing 10% fetal bovine serum and 1% penicillin/streptomycin. Cultured
cells were kept in 5% CO2 at 37°C. Trypan blue exclusion assay was done to determine
cell viability.
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3.2.2 Animal Model
To deliver brain tropic MDA-MB-231-BR cells into the brain, intra-cardiac (IC)
injection method was used to distribute cells through arterial circulation. Female nu/nu
mice (N=18, 6–8 weeks old; Charles River Laboratories) were anesthetized with 1.5 to
2% vaporized inhaled isoflurane in O2. A suspension containing 1.5x105 MDA-MB-231BR cells was slowly injected into the left ventricle of the beating heart of the mouse.[31]
This study followed animal care protocols approved by the Animal Use Subcommittee of
The University of Western Ontario and were consistent with the policies of the Canadian
Council on Animal Care (Appendix A: Animal Use Protocol).
Table 3-1: Irradiation group schedule for acute and longitudinal study. 0* = Unirradiated half brain of the mice.

Study

Acute

Longitudinal

Group

Number of
Mice

Number of tumors
on MRI

Dose
(Gy)

Dissection after
radiation therapy

A

3

>90

8

30 minutes

B

3

>90

16

30 minutes

C

4

>120

24

30 minutes

D

8

>200

0*

30 minutes

A

3

68

16

11 days

B

2

34

24

11 days

C

5

123

0*

11 days

Control

3

10

0

11 days

48

3.2.3 In-Vivo MRI
All mice were imaged on a 3T GE Excite clinical MR scanner (General Electric,
Mississauga, Canada) on day 26 after tumor injection. MRI was performed to verify the
presence of the tumors in the mouse brain, particularly in both brain hemispheres. Images
were acquired using 3D balanced steady-state free precession (bSSFP) protocol (Slice
thickness = 200µm, resolution = 100 x 100 x 200µm, repetition time = 8 ms, echo time =
4 ms, flip angle = 35°, receive bandwidth = 19.23 kHz, signal averages = 2,
radiofrequency phase cycles = 8, scan time = 29 minutes), a well-established imaging
technique for this model by Foster et al.[32–34] A small tube filled with vitamin E was used
on the left side of the animal in the head coil to assist with the head orientation on MR
images.
To evaluate the response of breast cancer brain metastases to different radiation
doses in-vivo, the longitudinal group was imaged again 11 days after receiving half brain
radiotherapy (37 days after injection). The same imaging protocol was used for postradiotherapy MR image acquisition.

3.2.4 Mouse Hemi-Brain Irradiation
Mice received half brain radiation therapy on the modified GE eXplore CT 120
(GE Healthcare, Milwaukee, WI) preclinical imaging system.[35,36] Mice were
anesthetized using 1.5 to 2% vaporized inhaled isoflurane. All mice were immobilized
using our customized 3D-printed head holder. We have previously demonstrated our
targeting accuracy of < 0.15 mm using this system (see Chapter 2). Mice were set-up in
feet first prone position. Longitudinal fissure (LF) was visually set as the anatomical
target for the radiation field. Setup lasers and CT images were used to verify the
alignment of the animal’s head in the head holder. Once the mouse was set-up for
treatment, online dorsal-ventral fluoroscopy was acquired to identify the rim of the skull
and positioning the collimators. To target for focal half brain irradiation, the
computerized collimators were moved, so the animal’s body, the left hemisphere of the
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brain and tumors within that side were shielded. A small ball bearing (BB) marker was
placed on the right side of the head holder to help with animal orientation on CT and
fluoroscopy. The right half of the brain was irradiated with a single field (14x20 mm2)
from the animal’s ventral-dorsal direction. Mice received doses of either 8, 16 or 24 Gy
in a single fraction. When we assumed that α/β ~ 10 Gy for the tumors, the calculated
biological effective dose (BED) of 16 Gy and 24 Gy in a single fraction are equal to
doses prescribed for whole brain radiation therapy and stereotactic radiosurgery in clinics
respectively. Figure 3-1 shows a representative dose distribution in the mouse brain for a
single fraction. The un-irradiated side of the brain and tumors within that half were
denoted as the 0* and considered the control of the irradiated side in the same mouse.
Mice recovered well from radiation and were selected either for acute or longitudinal
dose-response study. Control (sham) cohort did not receive radiation nor CT scans and
was the control of un-irradiated side.

Figure 3-1: Radiation dose-response experimental design. Tumors (MDA-MB-231BR) were injected on day 0. Twenty-six days after injection, all mice were imaged
with MR and selected either for acute or longitudinal study. In the acute study, mice
were scarified 30 minutes after receiving half brain radiotherapy. In the
longitudinal cohort, mice were imaged 11 days after RT and were sacrificed.
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Coronal view of the mouse head

3D-printed mouse head holder

Figure 3-2: Calculated dose distribution on coronal CT plane of the mouse brain.
Most of the right half of the brain received 16 Gy that matches with pink isodose
line.

3.2.5 Immunohistochemistry
At the two post-irradiation time-points (30 minutes or 11 days) mouse brain
samples were collected and processed for immunohistochemistry (IHC) staining. Mice
were perfused with 0.9% saline followed by 4% paraformaldehyde (PFA). Brains were
harvested, post-fixed in 4% PFA and transferred to 30% sucrose solution until the
specimen sank to the bottom. Brain samples were embedded in Tissue-Tek OCT
Compound (Sakura, Torrance, CA) and frozen. Cyrosectioning of coronal slices was
performed with 10-µm slice thickness. Tissue sections were stained with hematoxylin and
eosin (H&E) to assess the morphology of the tumors.
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Immunostaining was performed with the primary monoclonal antibody against γH2AX using a protocol published by Ford et al.[37] Briefly, sections were incubated with
mouse anti-γ-H2AX antibody (anti-phospho-histone H2AX, Ser139, clone JBW301;
Millipore, Billerica, MA, USA) at the dilution of 1:700 at 4˚C overnight and stained with
secondary antibody Alexa-Fluoro 594 goat anti-mouse IgG (Life Technologies, Carlsbad,
CA, USA) at the dilution of 1:500 for one hour at room temperature. DNA
counterstaining was achieved with incubation in DAPI (4', 6-diamidino-2-phenylindole)
and sections were mounted with anti-fade mounting medium Vectashield (Vector
Laboratories, Inc. Burlington, ON). Detailed staining protocol is described in Appendix
B. This protocol was used consistently to stain sections from the two time-points. For
quantification, images were acquired with 100X (oil immersion) objective lens on a
fluorescence microscope (Carl Zeiss Canada Ltd). Imaging acquisition parameters such
as intensity, exposure time and gain were kept consistent during the experiment. We
collected a total of ten to thirteen images of different tumors for each mouse.
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3.2.6 Histological Quantification
To evaluate the DNA damage response, γ-H2AX stained sections of tumors were
analyzed for each radiation dose. The amount of damage was also quantified in
neighboring normal brain tissue that were treated under the same condition as tumors.
The common approach for γ-H2AX quantification is scoring foci in the nuclei using
high-resolution 3D images acquired from the confocal microscope.[38] Initially, we
employed this method and acquired images from the inverted confocal microscope
(Olympus Fluoview FV1000 Confocal Imaging System). Figure 3-2 shows the images
from irradiated tumors for both acute and longitudinal studies. We observed in the acute
setting γ-H2AX foci were over-lapping, especially for high radiation doses, which made
detection of individual foci impossible. Similarly, foci saturation was observed in some
of the irradiated tumors in the longitudinal experiment. Unable to count individual foci,
we quantified γ-H2AX based on the fluorescent stain intensity, which is a more reliable
method for high radiation doses.[39,40]

Figure 3-3: Merged DAPI and γ-H2AX tumor sections taken from the confocal
microscope. (Blue=DAPI, Red= γ-H2AX) A: 30 minutes after irradiating tumors
with 16 Gy. Discrete foci were not distinguishable in the acute experiment. B: 11
days after irradiating tumors with 16 Gy. Overlapping foci were also detected in
some of the irradiated tumors nuclei.
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All IHC analyses were performed on images taken from fluorescence microscope
using 100X oil immersion objective. The γ-H2AX intensity was measured for both
mouse normal brain and tumor tissues. Tumor nuclei were distinguished from mouse
nuclei based on characteristic punctuate pattern of mouse DAPI staining.[41] To quantify
γ-H2AX intensity, DAPI-stained nuclei were used to generate nuclear outlines in which
the γ-H2AX intensity would be measured. Nuclear segmentations were used to eliminate
signal from background fluorescence. Nuclei on DAPI images were manually segmented
using Adobe Photoshop CC. For each field of view, total γ-H2AX fluorescence intensity
was automatically obtained by summing the values of all pixels within the segmented
boundary using an in-house code developed in MATLAB (MathWorks, Natick, MA,
USA). The total γ-H2AX fluorescence intensity for each field of view was normalized to
the total area of segmented nuclei for the same field (Equation 3-1):
                γ-‐H2AX  fluorescence  intensity  per  unit  area   =

Total  γ-‐H2AX  intensity  in  segmented  nuclei
Total  area  of  segmented  nuclei

    

(3-1)

Mean γ-H2AX intensity per unit area was determined for each treatment
condition. The total number of nuclei analyzed for each dose level varied from 350 to
950. Moreover, we assessed the size of tumor nuclei by computing the average area of
each nucleus from DAPI images (Equation 3-2):
Average  area  per  tumor  nucleus   =   

Total  area  of  segmented  nuclei
Number  of  segmented  nuclei

  

(3-2)

We observed that MDA-MB-231-BR tumors grew in clusters surrounded by
edema. We obtained number of tumor nuclei per cluster area. This index gave us the
density of tumor nuclei/cells in each cluster (Equation 3-3):
Tumor  cell  density   =

Number  of  tumor  nuclei  in  cluster
            
Area  of  segmented  cluster
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(3-3)

We quantified both the tumor cell density and size of tumor nucleus for all
radiation doses at the two time-points. Figure 3-3 shows the flow chart of the processes
involved in these histological quantifications. IHC staining was repeated three times for
the acute study and twice for the longitudinal study. Quantitative analyses of the latest set
of stains will be presented.

Figure 3-4: Flow chart of the processes involved in the quantification of γ-H2AX
intensity, tumor nucleus size and tumor cell density. DAPI and γ-H2AX images were
overlaid and nuclei were segmented based on DAPI. From the segmented DAPI
images, number and total area of segmented nuclei were quantified. The intensity of
γ-H2AX from segmented nuclei was acquired. For tumor cell density analysis,
tumor clusters were segmented based on DAPI and the area of the cluster was
computed.
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3.2.7 MRI Analysis
Brain metastases were segmented manually on pre and post-radiotherapy images
by a single observer using open-source OsiriX image software version 6.0. Tumors in the
midline of the brain (±200 µm of the longitudinal fissure) were excluded from the study
as only part of the tumors may be irradiated and part not. To determine the response of
brain metastasis to radiation therapy on MR images, the mean fractional volume changes
of the tumors were calculated. This index was calculated by dividing the tumor volume
(mm3) 11 days after treatment by the volume of the same tumor before treatment and
averaged for all brain metastasis for mice in each group.

3.2.8 Statistics
Statistical analyses were performed using SPSS (Armonk, NY: IBM Corp) and
confirmed by GraphPad Prism (La Jolla, CA, USA) software. Between-groups analysis of
variance (ANOVA) followed by Tukey post-hoc test was conducted to determine
whether the response was statistically significant (p < 0.05) between radiation dose levels
for both ex-vivo and in-vivo studies.

3.3 Results
3.3.1 γ-H2AX Radiation Dose-response
Formation of γ-H2AX in the nuclei of cells is one of the primary responses to
radiation-induced DNA DSBs. In the acute radiation dose-response study, mice received
half brain radiation of 8, 16 and 24 Gy (minimum N=3 per dose) and were sacrificed
approximately 30 minutes after treatment. Histology sections were stained for γ-H2AX to
quantify the initial damage induced in both normal brain and tumors. Figure 3-4 displays
mouse whole brain coronal section, which received half brain radiation of 16 Gy.
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Left

Right

Figure 3-5: Whole brain image of γ-H2AX stained brain section (red), imaged at
10X. DAPI counterstaining of DNA is shown in blue. Stable EGFP labeled tumors
are in green (white arrows). The intended target was the right half of the brain.
White dashed line shows longitudinal fissure, the anatomical radiation target. γH2AX stain shows the sharp edge of the beam in the middle of the brain and
demonstrates the tumor on the right side is irradiated while the ones on the left are
spared.
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Figure 3-5 shows the histology sections of tumors and normal brain tissue stained

8 Gy

16 Gy

24 Gy

0* Gy

8 Gy

16 Gy

24 Gy

γ-H2AX

DAPI

γ-H2AX

0* Gy

DAPI

Mouse normal brain cells

MDA-MB-231-BR

with DAPI and γ-H2AX for the acute study.

Figure 3-6: Initial DNA damage response 30 minutes post-irradiation. Histology
sections of fluorescent γ-H2AX and corresponding DAPI (nuclei) stained for tumor
(MDA-MB-231-BR) and normal brain are shown. Images were taken with the
fluorescence microscope (100X objective) Scale bar=50µm
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In general, the γ-H2AX images exhibited increasing intensity with radiation dose.
Figure 3-6 shows the quantification of γ-H2AX based on fluorescence intensity in normal
brain and tumor tissues. In normal brain, the amount of γ-H2AX intensity increased
linearly (R2= 0.78, p <0.001) with increasing radiation dose. However, in tumors this
trend stopped at 16 Gy and the level of γ-H2AX intensity dropped for the dose of 24 Gy.
The γ-H2AX intensity between irradiated and un-irradiated sides was significantly

Mean γ-H2AX intensity per area

different in both tumors and normal brain.

Mean γ-H2AX intensity per area- Acute
25

*

*

20

*

*

15

NS

MDA-MB-231-BR
Mouse normal brain cells

*

* *

*

NS

10
5
0

0*(8)

0*(16)

0*(24)

8

16

24

Dose(Gy)

Figure 3-7: Quantification of the intensity of γ-H2AX staining versus radiation dose
30 minutes after radiotherapy. Green bars indicate tumors and blue bars are
neighboring normal brain tissue. In normal brain nuclei, the γ-H2AX intensity was
significantly different for all radiation doses and had a linear trend. In tumors, γH2AX dropped down for the dose of 24Gy. *= p ≤ 0.05, Error bar = standard error
of the mean
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To evaluate the amount of residual γ-H2AX 11 days after hemi-brain radiation,
and to investigate how much of the initial damage is retained in both tumors and normal
brain tissues, γ-H2AX intensity was measured for longitudinal group (Figures 3-7, 3-8).

MDA-MB-231-BR
0 Gy(sham)

16 Gy

0*(24) Gy

24 Gy

Mouse normal brain cells
0 Gy(sham)
0*(16) Gy

16 Gy

0*(24) Gy

24 Gy

DAPI

γ-H2AX

DAPI

γ-H2AX

0*(16) Gy

Figure 3-8: Residual DNA damage response 11 days post-irradiation. Histology
sections of fluorescent γ-H2AX and corresponding DAPI (nuclei) staining for MDAMB-231-BR and normal brain are shown. Images were taken with the fluorescence
microscope (100X objective) Scale bar=50µm
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Mean γ-H2AX intensity per area

Mean γ-H2AX intensity per area - Longitudinal
MDA-MB-231-BR
15

Mouse normal brain cells

**** ***
***

10

**
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0

0

0*(16)

0*(24)

16

24

Dose(Gy)

Figure 3-9: Quantification of the intensity of γ-H2AX staining for the various
radiation dose 11 days after radiotherapy. Green bars indicate tumors and blue
bars are neighboring normal brain tissue. In normal brain, γ-H2AX intensity
decreased to the background level. In irradiated tumors, γ-H2AX intensity was
higher than both the background level and tumors in the un-irradiated side. **= p ≤
0.01, ***= p ≤ 0.001, ****=p ≤ 0.0001, Error bar= standard error of the mean

We observed that the amount of γ-H2AX returned to the background level in
irradiated normal brain nuclei 11 days after radiotherapy but not in the irradiated tumors.
There was no significant difference in the amount of residual γ-H2AX between irradiated
tumors (16 Gy vs. 24 Gy). However, irradiated tumors had higher levels of γ-H2AX
compared to tumors in the contralateral un-irradiated sides (0*(16) and 0*(24) Gy).
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3.3.2 Tumor Cell Nuclear Size
The DAPI stain binds to A-T base pairs and is used as a counterstain for the
chromosome and nucleus of the cell. For this reason, we used this stain to investigate the
size of tumor nuclei for both acute and longitudinal studies. We observed that the nuclei
of treated tumors were significantly larger than the un-treated nuclei 11 days after
radiotherapy. Figure 3-9 shows the different morphological appearances of irradiated
versus un-irradiated tumor nuclei stained with DAPI.

A

B

C

D

Figure 3-10: DAPI staining of tumor nuclei 11 days after radiotherapy. (A, B):
Tumors in the same section of the mouse brain, A: Un-irradiated side, B: Irradiated
with 16 Gy. (C, D): Tumors in the same section of the mouse brain, C: Un-irradiated
side, D: Irradiated with 24 Gy. 100X magnification. Scale bar=50µm
The size of tumor nuclei was quantified for both acute and longitudinal studies. The acute
setting quantification was employed to establish a baseline. Figure 3-10 shows the
average size of tumor nuclei 30 minutes after treatment. No significant difference was
found between groups. However, in the longitudinal cohort, there was a significant
difference in the size of the nuclei between treated and un-treated side of the same mice
and between two radiation doses of 16 and 24 Gy (Figure 3-11).
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Figure 3-11: Average size of tumor nuclei 30 minutes after radiotherapy. No
significant difference was found between groups. Error bar= standard error of the
mean
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Figure 3-12: Average size of tumor nuclei 11 days after radiotherapy. There was a
significant difference between the size of tumor nuclei treated with 16 Gy versus
their contralateral side. The same significance was seen for the dose of 24 Gy. The
amount of radiation dose also played a significant role in the size of tumor nuclei
between 16 and 24 Gy. No significance (NS) was found between un-irradiated sides
of the two doses and the sham group. *= p ≤0.05, ***= p ≤0.001, ****= p ≤0.0001,
Error bar= standard error of mean
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3.3.3 Tumor Cell Density
We observed on H&E samples from the longitudinal cohort that irradiated tumor
clusters are less compact, and surrounded by more substantial amount of edema
compared to tumor clusters on the un-irradiated side (Figure 3-12).

A

B

C

D

Figure 3-13: H&E stained sections of tumors 11 days after radiotherapy. (A, B):
Tumors in the same section of the mouse brain, A: Un-irradiated side, B: Irradiated
with 16 Gy. (C, D): Tumors in the same section of the mouse brain, C: Un-irradiated
side, D: Irradiated with 24 Gy. 10X magnification.
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In order to quantify this histological observation, we calculated tumor cell density
based on DAPI staining. We measured this index for both acute and longitudinal settings
in tumors. Figure 3-13 shows the tumor cell density on day 26. No significant difference
was detected in the density between treated and un-treated tumors and different radiation

Tumor cell density (#nuclei/cluster area)

doses 30 minutes after radiation therapy.

Tumor cell density - Acute
0.00015

0.00010

0.00005

0.00000

0*(8)

0*(16)

0*(24)

8

16

24

Dose(Gy)

Figure 3-14: The tumor cell density 30 minutes after radiotherapy. No significant
difference was found between the irradiated and un-irradiated groups. Error bar=
standard error of the mean

On the other hand, we found a significant difference between treated and untreated tumors in the longitudinal experiment. Figure 3-14 plots the average tumor cell
densities 11 days after radiotherapy. These results suggest that the population of tumor
nuclei per area of a cluster significantly decreased after radiotherapy. Histology samples
of n ≥ 2 mice were analyzed for each group. Furthermore, when we compare tumor cell
density between longitudinal irradiated and that in the acute setting, we found that at 16
and 24 Gy, the tumor density at day 11 is about half that of the acute settings.
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Tumor cell density - Longitudinal
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Figure 3-15: The tumor cell density 11 days after radiotherapy. The density for
tumors treated with 24 Gy was lower than other groups and significant with the untreated side. The same significant difference was found between tumors treated with
16 Gy and the un-treated side. There was a significant difference between treated
tumors. No significance was observed between the tumor cell density of control
(sham) and un-irradiated side of 16 Gy. *= p ≤ 0.05, ***= p ≤ 0.001, ****= p ≤
0.0001, Error bar= standard error of the mean

3.3.4 In-vivo Dose-Response
To assess the changes in the volume of tumors in response to radiation doses in- vivo,
MR images were taken before and 11 days after half brain radiation therapy.
Representative images of brain metastases at two different time-points for doses of 16
and 24 Gy and control (sham) are shown (Figure 3-15).
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Figure 3-16: MR images (bSSFP) of the mouse brain at two-time points. Metastases
appear as hyper-intense (bright) regions compared to brain parenchyma. Day 26
shows pre-treatment images and day 37 is 11 days after radiation therapy for the
same mouse. Right half of the brain was irradiated. One mouse per group is shown.
Red arrows indicate the brain metastases in the irradiated side (i.e. received
radiation) while green arrows show brain metastases in the un-irradiated side.
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The tumor segmentation on MR images at the end-point of the longitudinal study
revealed that the tumor volume increased whether they received radiation or not. The
mean fractional growth of the tumors was calculated for each group (Figure 3-16). There
was a statistically significant difference between the growth of un-irradiated 0*(16 Gy)
and irradiated brain metastases for dose of 16 Gy. While there was a trend, no significant
difference in the fractional growth on MR was found for dose of 24 Gy and tumors in
their counterparts 0*(24 Gy) and between the treated tumors at 16 and 24 Gy. Lastly, we
found a significant difference between 0 (sham) and un-irradiated sides 0*(16 and 24
Gy).

Tumor mean fractional growth

Tumor mean fractional growth on MRI - Longitudinal
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Figure 3-17: The mean fractional growth of brain metastases measured on MR
images for various radiation doses. On average tumors in the sham cohort and unirradiated sides 0*(16) and 0*(24) Gy grew 9.5±1.5, 5.7±0.3 and 4.4±0.5 (std. error of
mean) times respectively. Tumors that received doses of 16 or 24 Gy grew by a
factor of 3.8± 0.3 and 3.1±0.25 (std. error of mean) respectively. There was a
significant difference between the growth of tumors irradiated with 16 Gy versus
their un-irradiated side. MRI detected no significant difference between the growth
of 16 and 24 Gy treated tumors longitudinally. A significant difference was observed
between sham group and tumors in un-irradiated sides. **= p ≤ 0.01, ***= p ≤ 0.001,
Error bar= standard error of the mean
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3.4 Discussion
In this study, we evaluated the response of triple-negative breast cancer brain
metastases to different radiation doses both ex-vivo and in-vivo at two time-points after
treatment.
In the acute experiment, mice were sacrificed 30 minutes after receiving radiation
doses of 8, 16 and 24 Gy. γ-H2AX was used as a marker to measure the amount of
induced DNA DSBs. The IR damages in normal brain and tumor cells were quantified for
each dose level and compared to the un-irradiated side. Previous studies have reported a
linear relationship between radiation dose and γ-H2AX foci number and/or relative
fluorescence intensity up to lethal dose of 100 Gy.[21,42] We showed that the amount of
damage detected by γ-H2AX fluorescence intensity indeed has a linear correlation with
radiation dose (R2= 0.78, p<0.001) in normal brain nuclei. On the contrary, this trend was
not observed in tumors. For the dose of 24 Gy in a single fraction, the amount of γ-H2AX
fluorescence intensity in tumors adjacent to normal brain tissue decreased. The γ-H2AX
saturation has been reported in dose-response experiments on tumor cell lines in-vitro for
high radiation doses.[43] One reason for the γ-H2AX reduction for the dose of 24 Gy may
be due to the micro-CT/RT dose rate. The dose rate used for this experiment was
approximately 0.2 Gy/minute and it took about 2 hours to deliver 24 Gy. The γ-H2AX
level is correlated with the dose rate, and it reaches a plateau if the cells get to the
damage-repair equilibrium state.[44,45] Moreover, the fact that γ-H2AX measures DNA
DSBs indirectly may also contribute to this observation. γ-H2AX acts as an amplifier to
recruit DNA damage response machinery immediately after the radiation insult and does
not necessarily show true physical DNA breaks.[46,47] Once the repair mechanism has
been activated, phosphorylation of more H2AX is not critical.[48] Interpreting our findings
according to this perspective, the initial radiation-induced phosphorylation of H2AX was
sufficient for repair mechanism activation and recruitment in irradiated tumors. Unlike
normal brain tissues, further radiation insults in tumors did not result in phosphorylation
of new H2AX protein implying a difference in the feedback mechanism of DSB repair
and sensing between normal mouse brain tissues and tumors. Similar results were also
observed by Mariotti et al.[48] They reported that the number of γ-H2AX foci delivered
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with 5 hours gap or more did not increase.[48] Indeed, reduced γ-H2AX intensity does not
necessarily means less damage to the tumors for the dose of 24 Gy versus 16 Gy.
In the longitudinal experiment, tumor models received hemi-brain radiation doses
of 16 and 24 Gy. We scanned them 11 days after treatment to detect changes in tumors on
MRI and histology.
Our longitudinal γ−H2AX results showed that in normal brain nuclei the γ-H2AX
level returns to the background level. However, irradiated tumors retained their higher
amount of γ-H2AX compared to the background and un-irradiated tumors 11 days after
radiotherapy. It has been shown that tumors that retain the induced γ-H2AX in the first 24
hours after radiotherapy are more likely to die.[49] To the best of our knowledge, this is
the first study to evaluate tumors’ residual γ-H2AX on histological samples
longitudinally. However, the time span of 11 days is sufficient for the damaged tumor
cells to die and be removed. We hypothesize that the remaining tumor cells are surviving
(positive for Ki-67, data not shown) but with higher residual γ-H2AX. We speculate the
remaining irradiated tumors have unstable genome due to their defective repair
mechanism and/or mutations induced after radiotherapy. Indeed, it has been shown that
tumors have an excessive amount of γ-H2AX.[24] There are a number of explanations for
high cryptogenic level of γ-H2AX in tumor cells such as dysfunctional telomeres, which
provides a signal for γ-H2AX and drives genomic instability.[50] Yu and colleagues have
also shown higher endogenous levels of γ-H2AX in the more aggressive and
heterogeneous tumor cell lines.[51] Our results show that the surviving irradiated tumors
are more tolerant of unrepaired and misrepaired DNA damage. However, this hypothesis
needs to be tested by investigating markers related to genomic instability in tumors.
Another finding of our study was the difference in the size of tumor nuclei after
radiotherapy. We observed the size of the nuclei increased in irradiated tumors. It has
been shown that radiation may induce nuclear abnormalities in tumors, which results in
clonogenic cell death.[52] However, these changes usually occur within a few days after
radiation and can lead to delayed cell death. Changes in the nuclei size of the irradiated
tumors 11 days after radiotherapy need to be investigated in more detail, but corroborated
with the above genomic instability hypothesis.
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Finally, we evaluated the response of treated and un-treated breast cancer brain
metastases with MRI. We showed all the tumors, whether treated or un-treated, grew at
least three times over the duration of 11 days. Moreover, no significant effect was seen
between fractional growth of tumors treated with 16 Gy versus 24 Gy as segmented on
MRI. The MDA-MB-231-BR cells are known to be edemic lesions. In the bSSFP
sequence the edema appears as hyper-intense regions, which have contributed to the
tumor volume segmentation. In contrast, histology sections of these tumors showed
irradiated tumor clusters are surrounded by pockets of edema, and the tumor cell density
decreased significantly with the amount of radiation dose. We also observed that the
tumor cell density in the irradiated tumors 11 days after radiotherapy is about half of the
un-irradiated side and acute setting. Therefore, edema may mask tumor responses
assessed by bssfp MRI as the irradiated tumors grew about 3 times in volume. In some
sense, this could be interpreted as pseudoprogression in brain metastases after radiation
therapy.[53] Pseudoprogression is an effect of ionizing radiation, which result in enlarging
lesions that mimics the tumor progression but stabilizes over time.[54]
Furthermore, we employed tumors in un-irradiated side of the mouse brain as the
control of the treated side. There was a significant difference between the growth rate of
the tumors in the control (0 Gy) group and tumors in the un-irradiated (0* Gy) sides.
Monte-Carlo dose simulation for the given treatment plan showed the un-irradiated side
received doses up to 1.7 Gy for hemi brain radiation (24 Gy) due to the scatter and beam
penumbra. This dose in the range of 1-2 Gy could have a role in the significant
differences seen between the growth of control (sham) and un-irradiated tumors. Another
possible hypothesis is the radiation-induced bystander effect. This phenomenon is
defined as the induction of biological effects in cells that are not directly irradiated but
are close to the irradiated ones.[55] In our study, this effect may have happened between
irradiated and un-irradiated tumors in the two hemispheres of the mouse brain.[56]
One of the limitations of this study was the tumor model itself. The growth of
MDA-MB-231-BR tumor is known to be exponential, and in most of the studies the endpoint for this model is less than 30 days after tumor injection.[57] However, to observe the
effect of radiation longitudinally we needed to keep the mice alive until 11 days post-
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treatment. This time-point corresponded to day 37 after injection, which is beyond the
typical end-point of this tumor model. This factor is the reason for the relatively small
size of our longitudinal cohort as we have lost animals before day 37.

3.5 Conclusions
Brain metastasis is a growing problem in breast cancer patients. New treatment
strategies for brain metastasis are necessary. Radiotherapy is an established treatment that
currently is used to treat a majority of brain metastasis patients. Fundamental
radiobiological questions provide and suggest evidence for further improvements and
optimization in the clinics. In this study, we evaluated the radiation dose-response of
triple-negative breast cancer brain metastases. We found in the acute setting that
γ−H2AX in tumors could be saturated at the higher dose level while normal mouse brain
tissue continues to increase phosphorylation of H2AX. In the longitudinal setting 11 days
after treatment, we found the response of irradiated tumors at both dose levels differed
from un-irradiated counterparts in γ−H2AX fluorescence intensity, tumor cell density,
and tumor nuclear size. Significant difference was found on MRI between radiated and
un-irradiated tumors for the dose of 16 Gy and a trend was seen for the 24 Gy In addition,
significant different was detected between two radiation doses of 16 and 24 Gy on the
DAPI histological quantification but not on MRI analyses. Our results give insight about
how triple-negative breast cancer brain metastasis respond to ionizing radiation and sets a
platform for further investigations with different cell lines and radiobiological questions.
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Chapter 4

4

Conclusions and Future Directions
This study used a biological marker for DNA double-stranded breaks and

noninvasive magnetic resonance imaging to evaluate and characterize the response of
breast cancer brain metastases to different radiation doses. To the best of our knowledge,
this is the first study to investigate the radiation dose-response in breast cancer brain
metastasis model. Custom designed 3D-printed mouse head holder facilitated the
irradiation of mouse half brain. This approach gave the advantage of investigating
radiation dose-response in half of the brain while using the other half as a control. The
work presented in this thesis provides a platform for further research in radiation effects
in-vivo. The sections below summarize the significant findings in this thesis and future
directions that can be followed.

4.1 Chapter 2
4.1.1 3D-Printed Mouse Holder: Summary
The deployment of laboratory findings and their translation into clinical setting is
supported by preclinical research. Recently in the field of radiation therapy, the
technological disparity between preclinical research and human advanced treatments has
decreased with the development of sophisticated small animals irradiators.[1] Although
most of these units are equipped with on-board image guidance to assist with the animal
positioning, this capability is not suffice for irradiating sub-regional anatomical parts of
the small animals.[2] The scale of targeting error can be appreciated when one considers
that for mouse hemispherical irradiation, we are aiming to irradiate 5 mm of the brain and
all structures within that half.
For the radiation dose-response study described in Chapter 3, we designed a
mouse head holder for the micro-CT/RT unit. We fabricated our device using 3D-printer
and evaluated our actual radiation targeting error in tissue from the intended anatomical
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target using immunohistochemistry. The γ-H2AX stain showed that on average our
targeting error was less than 0.15 mm. The 3D-printed mouse head holder helped to
alleviate the concern of targeting accuracy for our study. Although many small animal
fixation devices have been introduced and evaluated by different groups, the unique
feature of this device is its design and the method of fabrication.[2–4] The work presented
sets the platform for using 3D-printing technology to build desired experimental devices
in a timely and cost-effective manner. In addition, it opens the prospect of sharing and
collaboration, as 3D-printers are now widely available.

4.1.2 Future Work
The custom designed head holder is dedicated to mouse irradiation on the microCT/RT couch. The present study performed hemi-brain irradiation. A future study can be
irradiating individual metastasis as identified with magnetic resonance imaging (MRI).
This will require pre-treatment MRI, cone beam CT just prior to radiation, fusion
between MRI and cone beam CT to guide beam placement, and irradiation. The design
can also be modified for other small animal models such as rats and/or other imaging
modalities. For instance, a multi-purpose restrainer can be designed for the rat glioma
model[5] that can serve both as a stereotactic device for tumor implant and as a holder for
radiotherapy and imaging.

4.2 Chapter 3
4.2.1 Acute Radiation Dose-Response Study: Summary
For the acute radiation dose-response study, mice were sacrificed 30 minutes after
various radiation doses. We employed γ-H2AX, as a marker that reflects the radiationinduced DNA double-stranded breaks.[6] The results showed γ-H2AX fluorescence
intensity in breast cancer brain metastases does not increase linearly with radiation dose
and, in fact, decreases at 24 Gy. In contrast, mouse normal brain cells showed a linear
trend between γ-H2AX fluorescence intensity and radiation dose. This finding generates
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new questions related to damage and repair signaling in tumors versus normal brain
tissues.

4.2.2 Acute Radiation Dose-Response Study: Future Work
We hypothesized that the saturation of γ-H2AX to radiation dose in the acute
study in MDA-MB-231-BR tumor model could be due to either the low dose-rate of our
unit or the γ-H2AX marker itself. To verify if it is the effect of dose-rate, one can
irradiate the whole brain of the same animal model with other irradiator units such as
Co60 and compare the induced γ-H2AX fluorescence intensity with what we have
presented. Moreover, tumors and normal brain tissues can be immune-stained for other
ionizing radiation-induced foci (IRIF) markers that are involved in DNA repair and DNA
damage signaling. Co-localization of γ-H2AX foci with tumor suppressor TP53 binding
protein 1 (53BP1) and/or Mre11 can be investigated.[7,8]

4.2.3 Ex-Vivo Longitudinal Radiation Dose-Response Study:
Summary
To investigate the radiation dose-response longitudinally after treatment, mice
were sacrificed 11 days after receiving half-brain radiation therapy. The histological
sections were stained for γ-H2AX to assess the residual amount of damage induced. The
results suggested:
1) Even after normalizing γ-H2AX by the area of nucleus, tumors that survived 11 days
after RT had significantly higher γ-H2AX intensity (Fig. 3-8) than the un-irradiated and
control tumors
2) Irradiated tumors had larger nuclei compared to the un-irradiated and control tumors
3) The amount of γ-H2AX returned to baseline level for normal brain nuclei
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4.2.4 Ex-Vivo Longitudinal Radiation Dose-Response Study: Future
Work
To the best of our knowledge, there is no clear reason why irradiated tumors
retained higher amount of γ-H2AX 11 days after radiotherapy. Our primary speculation is
the remaining surviving irradiated tumors are more genomic unstable compared to unirradiated ones. As for their large nuclei, one reason can be due to the chromosome
segregation error during mitosis that resulted in aneuploidy. Staining for markers such as
γ-tubulin would evaluate centrosome amplification and aneuploidy in irradiated tumors.
[9,10]

Another interesting approach can be related to the chromatin structure and its
architecture in the tumors after radiation. It has been shown that the structure of the
chromatin plays a pivotal role in DNA DSBs repair. Chromatin global relaxation happens
as early as 1 hour post-radiation to facilitate the repair mechanism.[11,12] The question
remains how this structure changes acutely in tumors after various doses of radiation and
if they also preserve their relaxed structure 11 days after radiotherapy. One of the
markers for the relaxed chromatin (euchromatin) state is acetylated histone 3 (H3).
Interesting, enhanced γ-H2AX foci have been correlated with abundant chromatinremodeling and histone hyperacetylation.[13] More investigation in this matter may be
beneficial for understanding the tumor recurrence after initial radiation therapy in patients
diagnosed with brain metastasis.[14]

4.2.5 In-Vivo Longitudinal Radiation Dose-Response Study:
Summary
For the in-vivo radiation dose-response study, mice were imaged with MRI bSSFP
sequence before and 11 days after treatment. The effect of radiation on the growth of
tumors was significantly different between treated and un-treated side for 16 Gy;
however, no significant difference was detected between two radiation doses of 16 and 24
Gy and 24 Gy and its contralateral part. In contrast, histological DAPI tumor cell density
showed significant difference between these two radiation doses.
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4.2.6 In-Vivo Longitudinal Radiation Dose-Response Study: Future
work
In the clinical setting, MRI is the gold standard imaging technique for patient
follow-up after treatment. Depending on the MRI sequence used, edemic parts of the
tumors can be misinterpreted to be positive lesions. The bSSFP sequence detects brain
metastases regardless of their permeability; however, this sequence also shows the
fluidity in the tumors as positive regions that can contribute to tumor segmentation and
volume.[15] Other MRI sequences such as diffusion-weighted imaging (DWI) can be used.
(Figure 4-1) The extracellular water molecules will have enhanced diffusion when the
tumor cell density decreases due to treatment, making this an interesting imaging marker
to assess radiation response.

Figure 4-1: Mouse brain tumor model imaged with DWI sequence on 9.4T scanner.
Images from two different b-values are shown. (a=500 s/mm2, b=1000 s/mm2)
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Appendices
Appendix A: Animal Use Protocol

Page 1 of 1

>>> eSiriusWebServer <esiriusadmin@uwo.ca> 2014/11/05 11:32 AM >>>

2009-080::5:
AUP Number: 2009-080
AUP Title: Non-Invasive Imaging of Metastasis: Detection, Monitoring and Intervention
Yearly Renewal Date: 11/01/2014
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2009-080 has been approved, and will be
approved for one year following the above review date.
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the ACVS office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar
with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety,
radiation safety, general laboratory safety) comply with institutional safety standards and have received all
necessary approvals. Please consult directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee

This information is directed in confidence solely to the person named above and may contain confidential and/or
privileged material. This information may not otherwise be distributed, copied or disclosed. If you have received
this e-mail in error, please notify the sender immediately via a return e-mail and destroy original message.
Thank you for your cooperation.
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Appendix B: Fluorescent γ-H2AX Immunohistochemistry
Standard Operating Procedure on Mouse Frozen Sections

**Everything at room temperature unless otherwise specified**
1) Antigen retrieval: Use 10mMol sodium citrate pH 6.0. Put the slides in a jar and pour
10 mMol Na citrate. Put the jar with slides in the microwave. Set the power to 10 and
watch until it boils. Then set the microwave power to 1 and set the timer for 10
minutes. Wait 30 minutes so that the slides get to room temperature.
2) Wash: 3 x 5 min PBS. Draw around each section with gnome pen (hydrophobic pen).
3) Blocking: 10% goat serum + 0.3% Triton + PBS: Apply blocking buffer and leave for
1 hour in the humid chamber.
4) Primary Antibody: Primary antibody is Millipore Anti-phospho-Histone H2AX mouse
(clone JBW301). The dilution is 1:700 in blocking buffer. For negative control do not
apply primary. Put the sections in the humid chamber and fridge (4°c) overnight.
5) Wash: 3 x 5 min in PBS.
6) Secondary Antibody: Alexa Fluor® 594 Goat Anti-Mouse IgG. Dilution is 1:500.
Rinse the slides and put the secondary. Put the slides in dark (heavy duty foil) for
1hour.
7) Wash: 3 x 5 min in PBS.
8) Counterstaining: Dry the slides and put 3 drops of DAPI Vectashield on cover glass
and flip the slides. Use nail polish to seal them and let them dry.
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